BioSpring and Phenion receive BMBF-Funding for the development of a bioactive for skin treatment

05-Aug-2005

The Frankfurt-based Biotech companies BioSpring GmbH and Phenion GmbH & Co. KG receive public funding of approximately 1 million Euro within the "BioChancePlus" funding program of the German Federal Ministry of education and Research (BMBF). The objective of the common research project is the development of nucleic acid derivatives (oligonucleotides) as topical bioactives for skin calming and treatment of inflamed skin.

During the project oligonucleotide molecules will be synthesized and characterized regarding to their biological activity in the skin within the Phenion®-Full Thickness Skin Model. For further development of suitable oligonucleotides the companies will search a strategic partnership e.g. with the pharmaceutical industry.

Other news from the department science

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance